Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

ZURZUVAE™ approved as first-and-only oral treatment specifically indicated for adults with postpartum depression and on-track for planned launch in the fourth quarter of 2023 shortly after DEA...

Related Keywords

Barry Greene ,Us Drug Enforcement Administration ,Exchange Commission ,Biogen Inc ,Drug Administration ,Early Development ,Sage Therapeutics Inc ,National Pregnancy Registry For Antidepressants ,Nasdaq ,European Medicines Agency ,Sage Therapeutics ,Chief Executive Officer ,Complete Response Letter ,Enforcement Administration ,New Drug Application ,Fast Track Designation ,Orphan Drug Designation ,Biogen Collaboration ,License Agreement ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended June ,National Pregnancy Registry ,Full Prescribing Information ,Medication Guide ,Controlled Substances ,Markets ,